Replies to post #91853 on Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

well spoken

AMBS has strength and is working from power - money is being "thrown around" - just like it was during the days of Cougar advancement and overnight multi-million dollar US military contracts to Force Protection....money is walking through Amarantus's front door - that is a fact...

"The in-license of Eltoprazine represents a major corporate milestone for Amarantus, moving the therapeutic pipeline from purely a pre-clinical pipeline with MANF, to a balanced pipeline with both clinical and pre-clinical assets," said David A. Lowe, PhD, member of the Amarantus Board of Directors. "The 5HT1a/1b pathway is emerging as a key biological pathway in the LID-space, and Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity."

Dr. David A. Lowe = Fidelity Investments

http://www.zoominfo.com/p/David-Lowe/1506858

"Dr. Lowe served as the Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group, Fidelity Investments in Boston, MA, an investment firm focused on the healthcare industry"

Fidelity BioScience VC

http://www.fidelitybiosciences.com/portfolio/index.php

Fidelity Biosciences invests venture capital in private biopharmaceutical, medical technology, and healthcare IT and services companies.

We are a division of Fidelity Investments, one of the world’s leading providers of financial services. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firms own capital since 1969. This provides us with the flexibility, and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value for Fidelity, our management partners, and co-investors.

We are engaged investors and board members, seeking to add value by providing strategic guidance and assistance to management throughout the process of building successful businesses. We possess the energy and entrepreneurial spirit of a start-up enterprise, while bringing to bear the considerable strengths and resources of Fidelity Investments.

**************************************************************************************************

I personally believe that Dr. Lowe is one of the few highly chosen and hand selected silent investors in the last tranche capital lift...

http://globenewswire.com/news-release/2013/11/14/590074/10058134/en/Amarantus-Reports-Third-Quarter-2013-Financial-Results-and-Development-Progress.html

On October 1, 2013 the Company closed on an additional $1.6 million in gross proceeds from its previous private placement of convertible debentures and warrants, bringing total gross proceeds from the private placement to $3.0 million. Cash and cash equivalents as of November 14, 2013, which are not reflected in the third quarter results, currently total approximately $1.7 million, which the Company intends to use as follows:

1. Complete the first LymPro clinical performance study;
2. Complete the reprioritization of MANF and complete additional IND-enabling work;
3. Allow the Company to operate through the first half of 2014;
4. Complete the in-licensure of certain intellectual property.

The Company also has the potential to raise up to an additional $5 million through the exercise of the warrants from the transaction, of which there can be no assurance, which would allow the Company to commercialize LymPro, file an IND for MANF in an orphan indication and initiate first-in-man studies, while operating into 2015.

[brickbybrick]

Completely in agreement with you on;

Bottom line: I cant see any reason why Gerald would announce this deal in relation to its current (and weak) cash position.